08
Oct
2012
HemaQuest Pharmaceuticals, Inc.: Series B $13M
Posted in I - Series B, Q - 1Q11, R - WEST, X - Beta Thalassemia, X - Hemoglobin, X - Sickle Cell, XX - CA
HemaQuest Pharmaceuticals (San Diego,CA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease and beta thalassemia closed a $13M Series B financing, bringing the total round to $25M. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures. Note: Closing out 1Q deals. Thanx for your patience as [...]
10
Jan
2012
Affinium Pharmaceuticals, Inc.: Series B $15M
Posted in I - Series B, Q - 3Q11, R - SOUTH WEST, X - Antibacterial, X - Antiinfective, X - MRSA, XX - TX
Affinium Pharmaceuticals (Austin, TX) a clinical-stage specialty pharmaceutical company focused on small molecule antibiotics targeting staph and MRSA infections, closed a $15M Series B financing. Participants include SV Life Sciences, Genesis Capital Partners, Forward Ventures and Ontario Emerging Technologies Fund. Thanx for your patience as we catch-up.
31
Aug
2011
Ambit Biosciences, Inc. Series D $30M
Posted in I - Series D, Q - 2Q11, R - WEST, X - Oncology, XX - CA
Ambit Biosciences (San Diego, CA) a clinical-stage biopharmaceutical company focused on kinase inhibitors for the treatment of cancer and other conditions, closed a $30M Series D financing. Participants include Apposite Capital, Perseus-Soros Biopharmaceutical Fund, OrbiMed, Forward Ventures, Roche Venture Fund, MedImmune Ventures, Gimv, GrowthWorks, GeneChem, Radius Ventures and NovaQuest Capital Management. The 2Q11 OnBioVC Trend [...]
25
Jun
2010
Nereus Pharmaceuticals, Inc.: Series E $20M
Posted in I - Series E, Q - 2Q10, R - WEST, X - Oncology, XX - CA
Nereus Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on non-small cell lung cancer and myeloma, closed a $20M Series E financing. Participants include HBM BioVentures, Alta Partners, Forward Ventures, Gimv, Advent International, Pacific Venture Group, Roche Venture Fund and Astellas Venture Management.
23
Apr
2010
HemaQuest Pharmaceuticals, Inc. Series B $12M
Posted in I - Series B, Q - 2Q10, R - NORTH EAST, X - Antiviral, X - EBV, X - Hemoglobin, X - HIV, X - HPV, X - Sickle Cell, XX - MA
HemaQuest Pharmaceuticals (Newton, MA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease, beta thalassemia, and viral-associated disease such as HPV, EBV and HIV, closed a $12M Series B financing. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.
13
Apr
2010
17
Mar
2010
Syndax Pharmaceuticals, Inc.: Series A $9M
Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - HDAC, X - Oncology, XX - MA
Syndax Pharmaceuticals (Waltham, MA) a clinical-stage pharmaceutical company focused on an HDAC inhibitor for solid tumors and hematological tumors, closed a $9M Series A financing, bringing the total round to $49M. Participants include Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures and Pappas Ventures.
16
Mar
2010
Syndax Pharmaceuticals, Inc.: Series A $9M
Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - HDAC, X - Oncology, XX - MA
Syndax Pharmaceuticals (Waltham, MA) a clinical-stage pharmaceutical company focused on an HDAC inhibitor for solid tumors and hematological tumors, closed a $9M Series A financing, bringing the total round to $49M. Participants include Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures and Pappas Ventures.
02
Feb
2010
Altair Therapeutics, Inc.: Series B $17M
Posted in I - Series B, Q - 4Q09, R - WEST, X - Asthma, X - Respiratory, X - Rhinitis, XX - CA
Altair Therapeutics (San Diego, CA) a clinical-stage biopharmaceutical company focused on antisense therapeutics for asthma and rhinitis, closed a $17M Series B financing. Participants include Domain Associates, AgeChem Venture Fund, Thomas McNerney & Partners and Forward Ventures. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb
OnBioVC PARTNERS
-
